Business
MedMira Reports Third Quarter Results FY2026
HALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported to...
About this update from Medmira Inc.
MedMira Reports Third Quarter Results FY2026HALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2026.Corporate updateDuring Q3 FY2026, the Company continued to advance the regulatory approval process for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). The Company received its initial feedback from Health Canada and remains confident that the new regulatory submission pathway will facilitate more efficient review timelines. Following the quarter, the second phase of clinical trials was completed, and the resulting data will be submitted to support the existing regulatory application. The test is also undergoing evaluation in multiple Canadian provinces to further demonstrate its clinical utility in guiding treatment decisions.The publication of clinical performance data for the Multiplo® TP/nTP has generated increased interest from stakeholders in international markets, including Australia and Latin America. The strong performance of the product further validates the Company's Rapid Vertical Flow (RVF) technology platform and supports future opportunities for specialized diagnostic products.Demand for rapid infectious disease diagnostic tests continued to increase throughout 2026, contributing to broader market opportunities for the Company's products.During the quarter, MedMira also initiated the regulatory approval process for its Health Canada-approved products in Australia under the Mutual Recognition Agreement between Canada and Australia, with similar initiatives underway in selected EMEA markets. These efforts are expected to accelerate market entry, expand the Company's international presence, and support long-term revenue growth.Profit and Loss HighlightsRevenue: The Company recorded revenues in Q3 FY2026 of $241,189 compared to Q2 FY2026 $24,503 and $59,117 in the same period last year. The Company recorded higher revenue due to sales in products and service revenue.Gross Profit: The Company recorded a gross profit in Q2 FY2026 of $176,409 compared to $18,132 in Q2 FY2026 and $43,011 in the same period last year.Operating expenses: The Company recorded for this quarter operating expenses of $441,218 compared to $423,180 in Q2 FY2026 and $772,776 in the same period last year.Net loss: The Company recorded...